Buffalo, NY10 Active Studies

Ankylosing Spondylitis Clinical Trials in Buffalo, NY

Find 10 actively recruiting ankylosing spondylitis clinical trials in Buffalo, NY. Connect with local research sites and explore new treatment options.

10
Active Trials
9
Sponsors
3,056
Enrolling

Recruiting Ankylosing Spondylitis Studies in Buffalo

RecruitingBuffalo, NYNCT04068649

Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer

This phase II trial studies how well single-fraction stereotactic body radiation therapy (SBRT) works when compared to standard radiation therapy in treating patients with cancer that has spread to ot...

1,500 participants
Roswell Park Cancer Institute
View Study Details
RecruitingBuffalo, NYNCT04910685

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants w...

534 participants
Blueprint Medicines Corporation
View Study Details
RecruitingBuffalo, NYNCT04787042

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatme...

316 participants
Simcha IL-18, Inc.
View Study Details
RecruitingBuffalo, NYNCT06744920

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment....

180 participants
Novartis Pharmaceuticals
View Study Details
RecruitingBuffalo, NYNCT05846789

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple negative...

168 participants
Kathy Miller
View Study Details
RecruitingBuffalo, NYNCT05735080

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to eval...

150 participants
Incyclix Bio
View Study Details
RecruitingBuffalo, NYNCT06191315

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

This is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmat...

90 participants
Sanofi
View Study Details
RecruitingBuffalo, NYNCT04150497

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The...

52 participants
Cellectis S.A.
View Study Details
RecruitingBuffalo, NYNCT04305834

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to othe...

43 participants
City of Hope Medical Center
View Study Details
RecruitingBuffalo, NYNCT04348747

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

This phase IIa trial studies how well dendritic cell vaccines against Her2/Her3 and pembrolizumab work for the treatment of triple negative breast cancer or HER2+ breast cancer or HER+ Breast cancer t...

23 participants
Roswell Park Cancer Institute
View Study Details

About Ankylosing Spondylitis Clinical Trials in Buffalo

Ankylosing spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and potentially spinal fusion. It typically begins in early adulthood. Treatment includes NSAIDs, biologics (TNF and IL-17 inhibitors), and physical therapy.

There are currently 10 ankylosing spondylitis clinical trials recruiting participants in Buffalo, NY. These studies are seeking a combined 3,056 participants. Research is being sponsored by Roswell Park Cancer Institute, Blueprint Medicines Corporation, Simcha IL-18, Inc. and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ankylosing Spondylitis Clinical Trials in Buffalo — FAQ

Are there ankylosing spondylitis clinical trials in Buffalo?

Yes, there are 10 ankylosing spondylitis clinical trials currently recruiting in Buffalo, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Buffalo?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Buffalo research site will contact you about next steps.

Are clinical trials in Buffalo free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Buffalo studies also compensate for your time and travel.

What ankylosing spondylitis treatments are being tested?

The 10 active trials in Buffalo are testing new therapies including novel drugs, biologics, and treatment approaches for ankylosing spondylitis.

Data updated March 2, 2026 from ClinicalTrials.gov